Unknown Lungs & Breathing NIHR-supported project Cancer

A randomised, open-label, multifactorial, multicentre, platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network

Funder NIHR (part of DHSC)
Recipient organisation NIHR Wellcome Trust Cambridge Clinical Research Facility
NIHR support Recorded as supported by this research centre
Period Feb 2025 — Ongoing

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Charles Haworth (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A randomised, open-label, multifactorial, multicentre, platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network. (AIR NET)
AIR-NET. A randomised, open-label, multifactorial, multicentre, platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network.
A randomised, open-label, multifactorial, multicentre, platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network. (AIRNET)
A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised, controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis
The EMBARC European Bronchiectasis Registry

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.